• 1
    Ushijima T,Sasako M. Focus on gastric cancer. Cancer Cell 2004; 5: 1215.
  • 2
    Nakajima T,Oda I,Gotoda T,Hamanaka H,Eguchi T,Yokoi C,Saito D. Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance? Gastric Cancer 2006; 9: 938.
  • 3
    Lee KJ,Inoue M,Otani T,Iwasaki M,Sasazuki S,Tsugane S. Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 2006; 118: 231521.
  • 4
    Kang CH,Yu TJ,Hsieh HH,Yang JW,Shu K,Huang CC,Chiang PH,Shiue YL. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003; 98: 16206.
  • 5
    Poon RT,Fan ST,Ng IO,Lo CM,Liu CL,Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 5007.
  • 6
    Yokoyama A,Omori T,Yokoyama T,Sato Y,Kawakubo H,Maruyama K. Risk of metachronous squamous cell carcinoma in the upper aerodigestive tract of Japanese alcoholic men with esophageal squamous cell carcinoma: a long-term endoscopic follow-up study. Cancer Sci 2008; 99: 116471.
  • 7
    Hartman M,Czene K,Reilly M,Adolfsson J,Bergh J,Adami HO,Dickman PW,Hall P. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 2007; 25: 42106.
  • 8
    Colice GL,Rubins J,Unger M. Follow-up and surveillance of the lung cancer patient following curative-intent therapy. Chest 2003; 123: S27283.
  • 9
    Rex DK,Kahi CJ,Levin B,Smith RA,Bond JH,Brooks D,Burt RW,Byers T,Fletcher RH,Hyman N,Johnson D,Kirk L, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2006; 130: 186571.
  • 10
    Braakhuis BJ,Tabor MP,Kummer JA,Leemans CR,Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 172730.
  • 11
    Maekita T,Nakazawa K,Mihara M,Nakajima T,Yanaoka K,Iguchi M,Arii K,Kaneda A,Tsukamoto T,Tatematsu M,Tamura G,Saito D, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006; 12: 98995.
  • 12
    Nakajima T,Maekita T,Oda I,Gotoda T,Yamamoto S,Umemura S,Ichinose M,Sugimura T,Ushijima T,Saito D. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 2006; 15: 231721.
  • 13
    Kondo Y,Kanai Y,Sakamoto M,Mizokami M,Ueda R,Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis—a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000; 32: 9709.
  • 14
    Shen L,Kondo Y,Rosner GL,Xiao L,Hernandez NS,Vilaythong J,Houlihan PS,Krouse RS,Prasad AR,Einspahr JG,Buckmeier J,Alberts DS, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005; 97: 13308.
  • 15
    Ishii T,Murakami J,Notohara K,Cullings HM,Sasamoto H,Kambara T,Shirakawa Y,Naomoto Y,Ouchida M,Shimizu K,Tanaka N,Jass JR, et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut 2007; 56: 1319.
  • 16
    Yan PS,Venkataramu C,Ibrahim A,Liu JC,Shen RZ,Diaz NM,Centeno B,Weber F,Leu YW,Shapiro CL,Eng C,Yeatman TJ, et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 2006; 12: 662636.
  • 17
    Arai E,Kanai Y,Ushijima S,Fujimoto H,Mukai K,Hirohashi S. Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer 2006; 119: 28896.
  • 18
    Enomoto S,Maekita T,Tsukamoto T,Nakajima T,Nakazawa K,Tatematsu M,Ichinose M,Ushijima T. Lack of association between CpG island methylator phenotype in human gastric cancers and methylation in their background non-cancerous gastric mucosae. Cancer Sci 2007; 98: 185361.
  • 19
    Perri F,Cotugno R,Piepoli A,Merla A,Quitadamo M,Gentile A,Pilotto A,Annese V,Andriulli A. Aberrant DNA methylation in non-neoplastic gastric mucosa of H. Pylori infected patients and effect of eradication. Am J Gastroenterol 2007; 102: 136171.
    Direct Link:
  • 20
    Calin GA,Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 85766.
  • 21
    Esquela-Kerscher A,Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 25969.
  • 22
    Lujambio A,Ropero S,Ballestar E,Fraga MF,Cerrato C,Setien F,Casado S,Suarez-Gauthier A,Sanchez-Cespedes M,Git A,Spiteri I,Das PP, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007; 67: 14249.
  • 23
    Kozaki K,Imoto I,Mogi S,Omura K,Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008; 68: 2094105.
  • 24
    Saito Y,Liang G,Egger G,Friedman JM,Chuang JC,Coetzee GA,Jones PA. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9: 43543.
  • 25
    Moriguchi K,Yamashita S,Tsujino Y,Tatematsu M,Ushijima T. Larger numbers of silenced genes in cancer cell lines with increased de novo methylation of scattered CpG sites. Cancer Lett 2007; 249: 17887.
  • 26
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd English edition. Gastric Cancer 1998; 1: 1024.
  • 27
    Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 3149.
  • 28
    Kaneda A,Kaminishi M,Sugimura T,Ushijima T. Decreased expression of the seven ARP2/3 complex genes in human gastric cancers. Cancer Lett 2004; 212: 20310.
  • 29
    Li B,Carey M,Workman JL. The role of chromatin during transcription. Cell 2007; 128: 70719.
  • 30
    Lin JC,Jeong S,Liang G,Takai D,Fatemi M,Tsai YC,Egger G,Gal-Yam EN,Jones PA. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 2007; 12: 43244.
  • 31
    Weisenberger DJ,Siegmund KD,Campan M,Young J,Long TI,Faasse MA,Kang GH,Widschwendter M,Weener D,Buchanan D,Koh H,Simms L, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 78793.
  • 32
    Ogino S,Odze RD,Kawasaki T,Brahmandam M,Kirkner GJ,Laird PW,Loda M,Fuchs CS. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol 2006; 30: 117583.
  • 33
    Issa JP,Ahuja N,Toyota M,Bronner MP,Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001; 61: 35737.
  • 34
    Ushijima T,Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from? Cancer Sci 2005; 96: 20611.
  • 35
    Yang N,Coukos G,Zhang L. MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment. Int J Cancer 2008; 122: 9638.
  • 36
    Uemura N,Okamoto S,Yamamoto S,Matsumura N,Yamaguchi S,Yamakido M,Taniyama K,Sasaki N,Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 7849.
  • 37
    Miyazaki T,Murayama Y,Shinomura Y,Yamamoto T,Watabe K,Tsutsui S,Kiyohara T,Tamura S,Hayashi N. E-cadherin gene promoter hypermethylation in H. pylori-induced enlarged fold gastritis. Helicobacter 2007; 12: 52331.